Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enabling and Disabling Polo-like Kinase 1 Inhibition through Chemical Genetics

15 Mar 2012

Abstract excerpt

Polo-like kinase 1 (Plk1) is a core regulator of cell division and an emerging target for cancer therapy. Pharmacologic inhibitors of Plk1 exist but affect other kinases, complicating their in vivo validation. To address this, we examined effects of two structurally unrelated Plk1 inhibitors (BI-2536 and TAL) against isogenic human cell lines that solely express wildtype (wt) or analogue-sensitive (as) Plk1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer-related Molecular Pathways
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22422077
DOI: 10.1021/cb200551p

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enabling and Disabling Polo-like Kinase 1 Inhibition through Chemical GeneticsPMID 22422077Read ↗

Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells.Semantic proximity Read ↗

Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.Semantic proximity Read ↗

Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implicationsSemantic proximity Read ↗

Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.Semantic proximity Read ↗

PLK-1 Targeted Inhibitors and Their Potential against TumorigenesisSemantic proximity Read ↗

Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS.Semantic proximity Read ↗

The CINs of Polo-Like Kinase 1 in CancerSemantic proximity Read ↗

A review of Plks: Thinking outside the (polo) boxSemantic proximity Read ↗

Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality InductionSemantic proximity Read ↗

Thoughts on the current assessment of Polo-like kinase inhibitor drug discoverySemantic proximity Read ↗

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeuticsSemantic proximity Read ↗

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in OncologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.